(Q33605532)

28 July 2017

title

Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. (English)

1 reference

28 July 2017

7

Dario Neri

1 reference

28 July 2017

5

Christoph Roesli

1 reference

28 July 2017

Roberto Sommavilla

1

1 reference

28 July 2017

Nadine Pasche

2

1 reference

28 July 2017

Eveline Trachsel

3

1 reference

28 July 2017

Leonardo Giovannoni

4

1 reference

28 July 2017

Alessandra Villa

6

1 reference

28 July 2017

Manuela Kaspar

8

1 reference

28 July 2017

publication date

15 June 2010

1 reference

Protein Engineering Design and Selection

28 July 2017

published in

1 reference

28 July 2017

volume

23

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

653-661

1 reference

Selective targeted delivery of TNFalpha to tumor blood vessels.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Biosynthesis and posttranslational regulation of human IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Antibody-cytokine fusion proteins: innovative weapons in the war against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Mammalian cell expression of dimeric small immune proteins (SIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Interleukin-12 as an adjuvant for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

A recombinant single-chain antibody interleukin-2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Design, construction, and characterization of a large synthetic human antibody phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ038

21 January 2018

Identifiers

DOI

10.1093/PROTEIN/GZQ038

1 reference

28 July 2017

1 reference